Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
8.14
-0.05 (-0.61%)
At close: Nov 20, 2024, 4:00 PM
8.23
+0.09 (1.11%)
Pre-market: Nov 21, 2024, 7:14 AM EST
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for IOVA stock have an average target of 23.33, with a low estimate of 10 and a high estimate of 34. The average target predicts an increase of 186.61% from the current stock price of 8.14.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IOVA stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +293.12% | Nov 6, 2024 |
| UBS | UBS | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +108.85% | Oct 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +293.12% | Aug 12, 2024 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $19 → $10 | Buy → Hold | Downgrades | $19 → $10 | +22.85% | Jul 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +293.12% | Jun 28, 2024 |
Financial Forecast
Revenue This Year
165.60M
from 1.19M
Increased by 13,827.67%
Revenue Next Year
469.80M
from 165.60M
Increased by 183.70%
EPS This Year
-1.29
from -1.89
EPS Next Year
-0.80
from -1.29
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 173.3M | 498.7M | 958.0M | ||
| Avg | 165.6M | 469.8M | 757.8M | ||
| Low | 155.8M | 429.1M | 602.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 14,471.1% | 201.1% | 103.9% | ||
| Avg | 13,827.7% | 183.7% | 61.3% | ||
| Low | 12,999.2% | 159.1% | 28.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.88 | -0.40 | 0.51 | ||
| Avg | -1.29 | -0.80 | -0.32 | ||
| Low | -1.46 | -1.31 | -1.15 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.